| Literature DB >> 24702684 |
Naiem T Issa1, Stephen W Byers, Sivanesan Dakshanamurthy.
Abstract
Advancements in genomics and personalized medicine not only effect healthcare delivery from patient and provider standpoints, but also reshape biomedical discovery. We are in the era of the '-omics', wherein an individual's genome, transcriptome, proteome and metabolome can be scrutinized to the finest resolution to paint a personalized biochemical fingerprint that enables tailored treatments, prognoses, risk factors, etc. Digitization of this information parlays into 'big data' informatics-driven evidence-based medical practice. While individualized patient management is a key beneficiary of next-generation medical informatics, this data also harbors a wealth of novel therapeutic discoveries waiting to be uncovered. 'Big data' informatics allows for networks-driven systems pharmacodynamics whereby drug information can be coupled to cellular- and organ-level physiology for determining whole-body outcomes. Patient '-omics' data can be integrated for ontology-based data-mining for the discovery of new biological associations and drug targets. Here we highlight the potential of 'big data' informatics for clinical pharmacology.Entities:
Mesh:
Year: 2014 PMID: 24702684 PMCID: PMC4448933 DOI: 10.1586/17512433.2014.905201
Source DB: PubMed Journal: Expert Rev Clin Pharmacol ISSN: 1751-2433 Impact factor: 5.045